2112, 2023
Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – November 2023
EMA October 18 – Trastuzumab deruxtecan – NSCLC HER2. The European Commission (EC) [...]
611, 2023
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – September and October 2023
EMA September 6 - Pembrolizumab – GC/GEJC HER2/PD-L1. The [...]
2806, 2023
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – April and May 2023
April 4. Tremelimumab + Durvalumab – NSCLC EGFR/ALK. The [...]
104, 2023
Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – February and March 2023
EMA February 28. Vandetanib – MTC RET. The European [...]
203, 2023
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – January 2023
FDA January 19. Tucatinib + trastuzumab – CRC RAS/HER2. [...]
1101, 2023
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November and December 2022
EMA November 9 - Selpercatinib – NSCLC/MTC RET. The [...]
1010, 2022
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – September2022
EMA September 16 - Nivolumab + relatlimab – melanoma [...]
809, 2022
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – August 2022
EMA August 4 – Olaparib – BC BRCA1/2. The European [...]